ArticleBioresources and bioprocessing2026
Purification-free antifungal biocontrol platform using engineered Saccharomyces cerevisiae secreting Trichoderma atroviride chitinase.
Article in Bioresources and bioprocessing, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chitinases from Trichoderma species exhibit strong antifungal activity and high biocontrol potential, yet their industrial utilization has been constrained by low heterologous secretion efficiency and costly purification processes. In this study, the Generally Recognized As Safe yeast Saccharomyces cerevisiae Y2805 was engineered to secrete chitinase Tch36 from a Korean isolate of T. atroviride, using a rice α-amylase signal peptide under a constitutive glyceraldehyde-3-phosphate dehydrogenase (GPD) promoter. When cultivated in glycerol–colloidal chitin medium, the recombinant yeast exhibited approximately a fivefold increase in measurable chitinase activity relative to the SC mock control, whereas the empty-vector control showed only a modest increase. The crude, non-concentrated culture filtrate (approximately 1000 U L⁻1) displayed statistically significant antifungal activity against 12 fungal species, including 9 phytopathogens and 3 opportunistic Aspergillus species. Among the phytopathogens, Fusarium graminearum was one of the most strongly inhibited species, showing approximately 40–50% suppression of colonial growth on solid medium. In liquid culture, microscopy-based germination assays revealed ≥ 63% inhibition of early hyphal elongation in Botrytis cinerea and A. niger. All antifungal effects were evaluated relative to filtrates from the empty-vector control prepared under equivalent dilution conditions. The culture filtrate also enhanced protoplast formation, providing direct evidence of chitinase-associated cell wall weakening. Collectively, these results establish a purification-free, yeast-based heterologous secretion platform capable of producing active Trichoderma chitinase with inhibitory effects on diverse plant- and animal-associated fungi. This strategy has practical potential for biocontrol applications and for sustainable bioprocessing technologies based on microbial chitinase production.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.